Lumiliximab

From Self-sufficiency

Revision as of 13:51, 29 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s))

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Lumiliximab
Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	CD23
Identifiers
ATC code	none
Chemical data
Formula	C₂₁₁₅H₃₂₅₂N₅₅₆O₆₇₃S₁₆
Molar mass	47.75 kDa[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Lumiliximab is a monoclonal antibody that targets CD23. It acts as an immunomodulator^[1] and, as of October 2009^[update], it is being investigated in Phase I and II clinical trials for the treatment of chronic lymphocytic leukemia.^[2]^[3] The drug is a chimeric antibody from Macaca irus and Homo sapiens.^[1]

References

Intracellular
(initiation)

Antimetabolites	purine synthesis inhibitor: Azathioprine · Mycophenolic acid pyrimidine synthesis inhibitor: Leflunomide · Teriflunomide antifolate: Methotrexate
Macrolides/ other IL-2 inhibitors	FKBP/Cyclophilin/Calcineurin: Tacrolimus · Ciclosporin · Pimecrolimus Abetimus · Gusperimus
TNF-α inhibitor	Thalidomide · Lenalidomide

Intracellular
(reception)

IL-1 receptor antagonists	Anakinra
mTOR	Sirolimus · Deforolimus · Everolimus · Temsirolimus · Zotarolimus · Biolimus A9

Extracellular

Serum target (noncellular)	Complement component 5 (Eculizumab) · TNFs (Infliximab, Adalimumab, Certolizumab pegol, Afelimomab, Golimumab) · Interleukin 5 (Mepolizumab) · Immunoglobulin E (Omalizumab) · BAYX (Nerelimomab) Interferon (Faralimomab) IL-6 (Elsilimomab) IL-12 and IL-23 (Lebrikizumab, Ustekinumab)
Cellular target	CD3 (Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) · CD4 (Clenoliximab, Keliximab, Zanolimumab) · CD11a (Efalizumab) · CD18 (Erlizumab) · CD20 (Afutuzumab, Ocrelizumab, Pascolizumab) · CD23 (Lumiliximab) · CD40 (Teneliximab, Toralizumab) · CD62L/L-selectin (Aselizumab) · CD80 (Galiximab) · CD147/Basigin (Gavilimomab) · CD154 (Ruplizumab) BLyS (Belimumab) · CTLA-4 (Ipilimumab, Tremelimumab) · CAT (Bertilimumab, Lerdelimumab, Metelimumab) · Integrin (Natalizumab) · Interleukin-6 receptor (Tocilizumab) · LFA-1 (Odulimomab) IL-2 receptor/CD25 (Basiliximab, Daclizumab, Inolimomab) T-lymphocyte (Zolimomab aritox)
Unsorted	Atorolimumab, Cedelizumab, Dorlixizumab, Fontolizumab, Gantenerumab, Gomiliximab, Maslimomab, Morolimumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Vapaliximab, Vepalimomab

-cept (Fusion)

proc, drug(L3/4)

v t e Chimeric monoclonal antibodies ("-xi-")
"-tuxi-" (tumor/cancer immunotherapy)	Bavituximab, Brentuximab vedotin, Cetuximab, Siltuximab, Rituximab
"-cixi-" (cardiovascular)	Abciximab, Volociximab
"-lixi-" (immune system)	Basiliximab, Clenoliximab, Galiximab, Gomiliximab, Infliximab, Keliximab, Lumiliximab, Priliximab, Teneliximab, Vapaliximab
"-mexi-" (melanoma)	Ecromeximab
"-baxi-" (bacterial)	Pagibaximab

This monoclonal antibody-related article is a stub. You can help ssf by expanding it.

40px	This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. v d e